Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology

Journal of Alzheimer's Disease

Volumn 52, Issue 3, 2016, Pages 863-873

  Beach, Thomas G ^a   Thal, Dietmar Rudolf ^b   Zanette, Michelle ^c   Smith, Adrian ^c   Buckley, Christopher ^c  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c GE HEALTHCARE   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid imaging; autopsy; diagnosis; preclinical; staging; 18F flutemetamol

Indexed keywords

AMYLOID PROTEIN; FLUTEMETAMOL F 18; ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; FLUTEMETAMOL; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; BRAIN CORTEX; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; NEUROIMAGING; NEUROPATHOLOGY; NORMOTENSIVE HYDROCEPHALUS; PARKINSON DISEASE; PARKINSONISM; PICK PRESENILE DEMENTIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STRIATE CORTEX; CLINICAL TRIAL; CORPUS STRIATUM; DIAGNOSTIC IMAGING; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; BENZOTHIAZOLES; CORPUS STRIATUM; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84971537741     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150732     Document Type: Article

References (39)

1. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688-1697
2. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE,Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106, 6820-6825
3. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452
4. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ (2009) Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132, 1310-1323
5. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ,Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, SkovronskyDM(2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283
6. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM(2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study. Lancet Neurol 11, 669-678
7. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S (2015) Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 72, 287-294
8. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, IronsideJW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ (2015) Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: Phase 3 study. Alzheimers Dement 11, 964-974
9. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368
10. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036
11. Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T (2010) Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett 473, 168-171
12. Beach TG, Kuo YM, Spiegel K, Emmerling MR, Sue LI, Kokjohn K, Roher AE (2000) The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 59, 308-313
13. Beach TG, Honer WG, Hughes LH (1997) Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: The preclinical stage of Alzheimer's disease? Acta Neuropathol 93, 146-153
14. Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, Beach TG (2011) Pre-and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol 122, 49-60
15. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M,Wolfson L (1988) Clinicopathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682-1687
16. Crystal HA, DicksonDW, Sliwinski MJ, Lipton RB, Grober E, Marks-Nelson H, Antis P (1993) Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 34, 566-573
17. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P,Yen SH, AronsonMK(1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13, 179-189
18. Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994) Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: A quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 4, 138-150
19. Braak H, Braak E (1997) Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 18, 351-357
20. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688-1693
21. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV (2012) Montine TJ National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8, 1-13
22. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging, Alzheimer's Association. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease:Apractical approach. Acta Neuropathol 123, 1-11
23. Braak H, Braak E (1990) Alzheimer's disease: Striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49, 215-224
24. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800
25. Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, Smith AP, Buckley C (2015) [F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 11, 975-985
26. Beach TG, Sue LI, Walker DG, Sabbagh MN, Serrano G, Dugger BN, Mariner M, Yantos K, Henry-Watson J, Chiarolanza G, Hidalgo JA, Souders L (2012) Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: Implications for amyloid imaging. J Alzheimers Dis 28, 869-876
27. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG (2012) Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: Usefulness for amyloid imaging. J Parkinsons Dis 2, 57-65
28. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA,Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27, 6174-6184
29. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Nagren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO (2008) PET amyloid ligand[11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 131, 1845-1853
30. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC (2009) High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 66, 1537-1544
31. Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, Flores DL, Apostolova LG, Barrio JR, Small G, Silverman DH, Siu E, Cederbaum S, Hecimovic S, Malnar M, Chakraverty S, Goate AM, Bird TD (2011) Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett 487, 287-292
32. Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE (2008) Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods 172, 277-282
33. Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, Mathis CA, Price JC, KlunkWE(2012) Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement 8, 496-501
34. Leinonen V, Rinne JO, Virtanen KA, Eskola O, Rummukainen J, Huttunen J, von Und Zu FM, Nerg O, Koivisto AM, Rinne J, Jaaskelainen JE, Buckley C, Smith A, Jones PA, Sherwin P, Farrar G, McLain R, Kailajarvi M, Heurling K, Grachev ID (2013) Positron emission tomography with[18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol 20, 1043-1052
35. Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, Smith A, McLain R, Sherwin PF, Farrar G, Kailajarvi M, Grachev ID(2012) [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: Pooled analysis of four studies. Acta Neuropathol 124, 833-845
36. Wong DF, Moghekar AR, Rigamonti D, Brasic JR, Rousset O, Willis W, Buckley C, Smith A, Gok B, Sherwin P, Grachev ID (2013) An in vivo evaluation of cerebral cortical amyloid with[18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol Imaging Biol 15, 230-237
37. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486
38. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del TK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404
39. Beach TG, Schneider JA, Sue LI, Serrano G, Dugger BN, Monsell SE, Kukull W (2014) Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol 73, 948-953